Find therapies in clinical trials near you – page 98

Study on Balcinrenone and Dapagliflozin for Patients with Heart Failure and Kidney Problems

Study on Balcinrenone and Dapagliflozin for Patients with Heart Failure and Kidney Problems

Study on the Effectiveness of Concizumab for Children Under 12 with Hemophilia A or B, With or Without Inhibitors

Study on the Effectiveness of Concizumab for Children Under 12 with Hemophilia A or B, With or Without Inhibitors

Study on Carisbamate for Treating Seizures in Children and Adults with Lennox-Gastaut Syndrome

Study on Carisbamate for Treating Seizures in Children and Adults with Lennox-Gastaut Syndrome

Study to Compare Datopotamab Deruxtecan with Rilvegostomig or Alone Against Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Study to Compare Datopotamab Deruxtecan with Rilvegostomig or Alone Against Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Long-Term Safety Study of GLM101 for Patients with PMM2-CDG

Long-Term Safety Study of GLM101 for Patients with PMM2-CDG

Study on Dinutuximab Beta with Chemotherapy for Children and Teens with Newly Diagnosed High-Risk Neuroblastoma

Study on Dinutuximab Beta with Chemotherapy for Children and Teens with Newly Diagnosed High-Risk Neuroblastoma

Study on the Effects of Finerenone in Patients with Heart Failure and Preserved Ejection Fraction Hospitalized for Acute Decompensated Heart Failure

Study on Datopotamab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic Endometrial, Gastric, Prostate, Ovarian, Colorectal, Urothelial, and Biliary Tract Cancers

Study of Lenvatinib, Pembrolizumab, and Chemotherapy Combination for Patients with Advanced Esophageal Cancer Previously Treated with PD-1/PD-L1 Therapy

Study of Lenvatinib, Pembrolizumab, and Chemotherapy Combination for Patients with Advanced Esophageal Cancer Previously Treated with PD-1/PD-L1 Therapy

Study on the Safety and Effects of Sparsentan for Children with Proteinuric Kidney Diseases

Study on the Safety and Effects of Sparsentan for Children with Proteinuric Kidney Diseases

Study on Efgartigimod for Children Aged 2-17 with Generalized Myasthenia Gravis

Study on Efgartigimod for Children Aged 2-17 with Generalized Myasthenia Gravis

Study of RMC-6236 and Pembrolizumab with or without Chemotherapy for Patients with RAS-Mutated Non-Small Cell Lung Cancer

Study of RMC-6236 and Pembrolizumab with or without Chemotherapy for Patients with RAS-Mutated Non-Small Cell Lung Cancer